Russell Investments Group Ltd. purchased a new stake in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 44,916 shares of the company's stock, valued at approximately $552,000. Russell Investments Group Ltd. owned 0.14% of NeuroPace as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in NeuroPace during the 4th quarter valued at $29,000. GAMMA Investing LLC purchased a new stake in NeuroPace during the 1st quarter valued at $53,000. Wells Fargo & Company MN raised its holdings in NeuroPace by 54.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after buying an additional 2,279 shares during the period. MetLife Investment Management LLC purchased a new stake in NeuroPace during the 4th quarter valued at $103,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in NeuroPace in the fourth quarter worth $112,000. Hedge funds and other institutional investors own 78.83% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the company. Wells Fargo & Company reduced their target price on NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. HC Wainwright assumed coverage on NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $17.00 target price on shares of NeuroPace in a research note on Wednesday, May 14th. JPMorgan Chase & Co. increased their target price on NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 14th. Finally, Zacks Research lowered NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.60.
View Our Latest Stock Report on NeuroPace
NeuroPace Stock Up 4.0%
NPCE stock traded up $0.37 during trading on Thursday, reaching $9.73. 103,623 shares of the company traded hands, compared to its average volume of 270,302. NeuroPace, Inc. has a 12 month low of $5.45 and a 12 month high of $18.98. The business has a 50 day simple moving average of $9.31 and a 200 day simple moving average of $11.34. The company has a market capitalization of $321.90 million, a price-to-earnings ratio of -11.54 and a beta of 1.90. The company has a debt-to-equity ratio of 3.02, a quick ratio of 4.51 and a current ratio of 5.47.
NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. The company had revenue of $23.52 million for the quarter, compared to the consensus estimate of $23.08 million. NeuroPace has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.
NeuroPace Company Profile
(
Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
See Also
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
